Gene Therapy Strategies for Alzheimer's Disease: An Overview

Human Gene Therapy

Volumn 27, Issue 2, 2016, Pages 100-107

  Alves, Sandro ^a   Fol, Romain ^a   Cartier, Nathalie ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID ANTIBODY; AMYLOID PRECURSOR PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CHOLESTEROL 24 HYDROXYLASE ENZYME; CHOLESTEROL ACYLTRANSFERASE; ENZYME; GAMMA SECRETASE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; INTERLEUKIN 10; MONOCLONAL ANTIBODY; NERVE GROWTH FACTOR; SOMATOMEDIN B; SOMATOMEDIN C; TRANSCRIPTION FACTOR NRF2; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2; UNCLASSIFIED DRUG; APOLIPOPROTEIN E; ASPARTIC PROTEINASE; BACE1 PROTEIN, HUMAN; NEUTRALIZING ANTIBODY; NFE2L2 PROTEIN, HUMAN; SECRETASE; SMALL INTERFERING RNA; SOMATOMEDIN;

ALZHEIMER DISEASE; AUTOPHAGY; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; ENZYME INHIBITION; GENE THERAPY; GENE TRANSFER; HEREDITY; HUMAN; LIPID METABOLISM; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PROTEIN METABOLISM; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BRAIN; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DISEASE MODEL; GENETICS; LENTIVIRINAE; METABOLISM; PATHOLOGY; PLAQUE, AMYLOID; PROCEDURES;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTIBODIES, NEUTRALIZING; APOLIPOPROTEINS E; ASPARTIC ACID ENDOPEPTIDASES; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENETIC THERAPY; HUMANS; LENTIVIRUS; NF-E2-RELATED FACTOR 2; PLAQUE, AMYLOID; RNA, SMALL INTERFERING; SOMATOMEDINS;

EID: 84958966849     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2016.017     Document Type: Review

References (62)

1. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991;12:383-388.
2. Hardy J, Bogdanovic N, Winblad B, et al. Pathways to Alzheimer's disease. J Intern Med 2014; 275:296-303.
3. Selkoe DJ. Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 2001;81:741-766.
4. Zhang YW, Thompson R, Zhang H, et al. APP processing in Alzheimer's disease. Mol Brain 2011;4:3.
5. Reitz C. Genetic diagnosis and prognosis of Alzheimer's disease: Challenges and opportunities. Expert Rev Mol Diagn 2015;15:339-348.
6. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in earlyonset familial Alzheimer's disease. Nature 1995; 375:754-760.
7. St George-Hyslop PH, Tanzi RE, Polinsky RJ, et al. The genetic defect causing familial Alzheimer's disease maps on chromosome 21. Science 1987; 235:885-890.
8. Bettens K, Sleegers K, Van Broeckhoven C. Genetic insights in Alzheimer's disease. Lancet Neurol 2013;12:92-104.
9. Van Broeckhoven C, Backhovens H, Cruts M, et al. Mapping of a gene predisposing to early-onset Alzheimer's disease to chromosome 14q24.3. Nat Genet 1992;2:335-339.
10. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 1993;90:1977-1981.
11. Spinney L. Alzheimer's disease: The forgetting gene. Nature 2014;510:26-28.
12. Karch CM, Goate AM. Alzheimer's disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry 2015;77:43-51.
13. Lee JH, Cheng R, Honig LS, et al. Association between genetic variants in SORL1 and autopsyconfirmed Alzheimer disease. Neurology 2008;70: 887-889.
14. Rogaeva E, Meng Y, Lee JH, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 2007; 39:168-177.
15. Offe K, Dodson SE, Shoemaker JT, et al. The lipoprotein receptor LR11 regulates amyloid beta production and amyloid precursor protein traffic in endosomal compartments. J Neurosci 2006;26:1596-1603.
16. Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 2013;45:1452-1458.
17. Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: Clinical implications and perspectives. Genet Med 2015. doi: 10.1038/gim.2015.117. [Epub ahead of print]
18. Mangialasche F, Solomon A, Winblad B, et al. Alzheimer's disease: Clinical trials and drug development. Lancet Neurol 2010;9:702-716.
19. Godyn J, Jonczyk J, Panek D, et al. Therapeutic strategies for Alzheimer's disease in clinical trials. Pharmacol Rep 2016;68:127-138.
20. Filser S, Ovsepian SV, Masana M, et al. Pharmacological inhibition of BACE1 impairs synaptic plasticity and cognitive functions. Biol Psychiatry 2015;77:729-739.
21. Singer O, Marr RA, Rockenstein E, et al. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci 2005;8:1343-1349.
22. Yan R, Vassar R. Targeting the beta secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol 2014;13:319-329.
23. De Strooper B. Lessons from a failed gammasecretase Alzheimer trial. Cell 2014;159:721-726.
24. Tan Y, Zhang Q, Wong SG, et al. Anti-Alzheimer therapeutic drugs targeting gamma-secretase. Curr Top Med Chem 2016;16:549-557.
25. Miners JS, Barua N, Kehoe PG, et al. Abetadegrading enzymes: Potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol 2011;70:944-959.
26. Carty NC, Nash K, Lee D, et al. Adeno-associated viral (AAV) serotype 5 vector mediated gene delivery of endothelin-converting enzyme reduces Abeta deposits in APP + PS1 transgenic mice. Mol Ther 2008;16:1580-1586.
27. Carty N, Nash KR, Brownlow M, et al. Intracranial injection of AAV expressing NEP but not IDE reduces amyloid pathology in APP+PS1 transgenic mice. PLoS One 2013;8:e59626.
28. Wisniewski T, Goni F. Immunotherapeutic approaches for Alzheimer's disease. Neuron 2015; 85:1162-1176.
29. Fukuchi K, Tahara K, Kim HD, et al. Anti-Abeta single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease. Neurobiol Dis 2006;23:502-511.
30. Weyer SW, Zagrebelsky M, Herrmann U, et al. Comparative analysis of single and combined APP/APLP knockouts reveals reduced spine density in APP-KO mice that is prevented by APPsalpha expression. Acta Neuropathol Commun 2014;2:36.
31. Weyer SW, Klevanski M, Delekate A, et al. APP and APLP2 are essential at PNS and CNS synapses for transmission, spatial learning and LTP. EMBO J 2011;30:2266-2280.
32. Ring S, Weyer SW, Kilian SB, et al. The secreted beta-amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP-deficient mice. J Neurosci 2007;27:7817-7826.
33. Endres K, Fahrenholz F. Regulation of alphasecretase ADAM10 expression and activity. Exp Brain Res 2012;217:343-352.
34. Fahrenholz F. Alpha-secretase as a therapeutic target. Curr Alzheimer Res 2007;4:412-417.
35. Deng J, Habib A, Obregon DF, et al. Soluble amyloid precursor protein alpha inhibits tau phosphorylation through modulation of GSK3beta signaling pathway. J Neurochem 2015;135:630-637.
36. Prox J, Rittger A, Saftig P. Physiological functions of the amyloid precursor protein secretases ADAM10, BACE1, and presenilin. Exp Brain Res 2012;217:331-341.
37. Fol R, Braudeau J, Ludewig S, et al. Viral gene transfer of APPsalpha rescues synaptic failure in an Alzheimer's disease mouse model. Acta Neuropathol 2016;131:247-266.
38. Nagahara AH, Merrill DA, Coppola G, et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med 2009;15:331-337.
39. Kordower JH,Winn SR, Liu YT, et al. The agedmonkey basal forebrain: Rescue and sprouting of axotomized basal forebrain neurons after grafts of encapsulated cells secreting human nerve growth factor. Proc Natl Acad Sci U S A 1994;91:10898-10902.
40. Counts SE, Nadeem M, Wuu J, et al. Reduction of cortical TrkA but not p75(NTR) protein in earlystage Alzheimer's disease. Ann Neurol 2004;56: 520-531.
41. Malkki H. Alzheimer disease: NGF gene therapy activates neurons in the AD patient brain. Nat Rev Neurol 2015;11:548.
42. Rafii MS, Baumann TL, Bakay RA, et al. A phase 1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. Alzheimers Dement 2014;10:571-581.
43. Tuszynski MH, Yang JH, Barba D, et al. Nerve growth factor gene therapy: Activation of neuronal responses in Alzheimer disease. JAMA Neurol 2015;72:1139-1147.
44. Altar CA, Cai N, Bliven T, et al. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 1997;389:856-860.
45. Narisawa-Saito M, Wakabayashi K, Tsuji S, et al. Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer's disease. Neuroreport 1996;7:2925-2928.
46. Revilla S, Ursulet S, Alvarez-Lopez MJ, et al. Lenti-GDNF gene therapy protects against Alzheimer's disease-like neuropathology in 3xTg-AD mice and MC65 cells. CNS Neurosci Ther 2014;20:961-972.
47. Pascual-Lucas M, Viana da Silva S, Di Scala M, et al. Insulin-like growth factor 2 reverses memory and synaptic deficits in APP transgenic mice. EMBO Mol Med 2014;6:1246-1262.
48. Mellott TJ, Pender SM, Burke RM, et al. IGF2 ameliorates amyloidosis, increases cholinergic marker expression and raises BMP9 and neurotrophin levels in the hippocampus of the APPswePS1dE9 Alzheimer's disease model mice. PLoS One 2014;9:e94287.
49. Kanninen K, Heikkinen R, Malm T, et al. Intrahippocampal injection of a lentiviral vector expressing Nrf2 improves spatial learning in a mousemodel of Alzheimer's disease. Proc Natl Acad Sci U S A 2009;106:16505-16510.
50. Pickford F, Masliah E, Britschgi M, et al. The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J Clin Invest 2008;118:2190-2199.
51. Maher FO, Nolan Y, Lynch MA. Downregulation of IL-4-induced signalling in hippocampus contributes to deficits in LTP in the aged rat. Neurobiol Aging 2005;26:717-728.
52. Kiyota T, Okuyama S, Swan RJ, et al. CNS expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer's disease-like pathogenesis in APP+PS1 bigenic mice. FASEB J 2010;24: 3093-3102.
53. Kiyota T, Ingraham KL, Swan RJ, et al. AAV serotype 2/1-mediated gene delivery of antiinflammatory interleukin-10 enhances neurogenesis and cognitive function in APP+PS1 mice. Gene Ther 2012;19:724-733.
54. Jiang T, Tan L, Zhu XC, et al. Upregulation of TREM2 ameliorates neuropathology and rescues spatial cognitive impairment in a transgenic mouse model of Alzheimer's disease. Neuropsychopharmacology 2014;39:2949-2962.
55. Dodart JC, Marr RA, Koistinaho M, et al. Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2005;102:1211-1216.
56. Hudry E, Dashkoff J, Roe AD, et al. Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. Sci Transl Med 2013;5: 212ra161.
57. Chang TY, Li BL, Chang CC, et al. Acyl-coenzyme A:cholesterol acyltransferases. Am J Physiol Endocrinol Metab 2009;297:E1-E9.
58. Murphy SR, Chang CC, Dogbevia G, et al. Acat1 knockdown gene therapy decreases amyloid-beta in a mouse model of Alzheimer's disease. Mol Ther 2013;21:1497-1506.
59. Ghribi O. Potential mechanisms linking cholesterol to Alzheimer's disease-like pathology in rabbit brain, hippocampal organotypic slices, and skeletal muscle. Journal of Alzheimer's disease: JAD 2008;15:673-684.
60. Hudry E, Van Dam D, Kulik W, et al. Adenoassociated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease. Mol Ther 2010;18:44-53.
61. Burlot MA, Braudeau J, Michaelsen-Preusse K, et al. Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with Alzheimer-like Tau pathology. Hum Mol Genet 2015;24:5965-5976.
62. Djelti F, Braudeau J, Hudry E, et al. CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer's disease. Brain 2015;138:2383-2398.